EULAV Asset Management’s CONMED CNMD Stock Holding History

EULAV Asset Management’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-14,900	Closed	-$1.19M	–	172
2024 Q1	$1.19M	Sell	14,900 -7,800	-34%	-$695K	0.03%	172
2023 Q4	$2.49M	Hold	22,700	–	–	0.08%	160
2023 Q3	$2.29M	Hold	22,700	–	–	0.08%	159
2023 Q2	$3.08M	Hold	22,700	–	–	0.12%	142
2023 Q1	$2.36M	Hold	22,700	–	–	0.09%	169
2022 Q4	$2.01M	Hold	22,700	–	–	0.09%	171
2022 Q3	$1.82M	Hold	22,700	–	–	0.08%	174
2022 Q2	$2.17M	Hold	22,700	–	–	0.09%	176
2022 Q1	$3.37M	Hold	22,700	–	–	0.1%	162
2021 Q4	$3.31M	Hold	22,700	–	–	0.08%	177
2021 Q3	$2.97M	Hold	22,700	–	–	0.08%	173
2021 Q2	$3.12M	Hold	22,700	–	–	0.08%	172
2021 Q1	$2.96M	Hold	22,700	–	–	0.08%	184
2020 Q4	$2.54M	Hold	22,700	–	–	0.07%	195
2020 Q3	$1.79M	Hold	22,700	–	–	0.05%	204
2020 Q2	$1.63M	Hold	22,700	–	–	0.05%	205
2020 Q1	$1.3M	Buy	22,700 +6,500	+40%	+$599K	0.05%	204
2019 Q4	$1.81M	Buy	16,200 +6,200	+62%	+$661K	0.06%	217
2019 Q3	$962K	Buy	+10,000	New	+$939K	0.04%	260

Other funds holding CNMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $113B AUM 34.64% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.3B AUM 29.38% 1-Year Est. Return

EULAV Asset Management's CNMD Position: Q2 2024 in Review

EULAV Asset Management sold out of CONMED (CNMD) in Q2 2024, closing a stake of 14,900 shares — an estimated $1.19M sold.

EULAV Asset Management first reported a position in CNMD in Q3 2019 and held it in 19 quarters. The position peaked at $3.37M in Q1 2022. 290 funds tracked by Wall St. Rank hold CNMD as of Q2 2024.

EULAV Asset Management reported no remaining CONMED position as of Q2 2024 after selling out during the quarter.
EULAV Asset Management sold 14,900 CONMED shares in Q2 2024, an estimated $1.19M.
EULAV Asset Management first reported a position in CONMED in Q3 2019 and held it in 19 quarters.
EULAV Asset Management's CONMED position peaked at $3.37M in Q1 2022.
290 funds tracked by Wall St. Rank held CONMED as of Q2 2024.

Based on EULAV Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.